|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||373.32 - 374.04|
|52-week range||308.57 - 411.44|
|Beta (5Y monthly)||0.27|
|PE ratio (TTM)||21.16|
|Forward dividend & yield||9.78 (2.63%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.
Roche's (RHHBY) Sparks enters into a collaboration agreement with NeuExcell Therapeutics to develop a novel gene therapy for HD.